It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:
Image source: Getty Images
James Hardie Industries plc (ASX: JHX)
According to a note out of Macquarie, its analysts have retained their outperform rating on this building products company's shares with a reduced price target of $36.90. This follows the release of a first quarter update which was materially below expectations. Macquarie notes that a rapid reversal in market conditions and inventory indigestion have combined to see the company reduce its FY 2026 guidance sharply. However, it remains positive. Macquarie acknowledges that market conditions are tough, but thinks an evolving AZEK integration story, a slow bottoming of markets, and another material price correction are in support of a reassessment. It also believes that balance sheet risks are elevated, but manageable. The James Hardie share price is trading at $30.53 this afternoon.
Sonic Healthcare Ltd (ASX: SHL)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this healthcare company's shares with a trimmed price target of $33.30. This follows the release of a mixed full year result this week. And while Sonic Healthcare missed consensus estimates for EBITDA by 2%, it thinks the selloff that ensued was an overreaction. Especially given that management is guiding to strong earnings growth in FY 2026. Overall, despite the market reaction, Bell Potter thinks its share price offers material upside for investors that appreciate steady compound earners. The Sonic Healthcare share price is fetching $24.88 at the time of writing.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another note out of Bell Potter reveals that its analysts have retained their buy rating on this pharmaceuticals company's shares with a trimmed price target of $30.00. This follows the release of its half year results, which were in line with expectations. In addition, Bell Potter was pleased to see management maintain its FY 2025 revenue guidance of $770 million to $800 million. It also highlights that a decision on its Zircaix approval is scheduled for 27 August and believes a launch is likely in 1Q26 if everything goes to plan. Overall, it feels that its long term strategy for growth remains in place and sees lots of value in its shares. The Telix share price is trading at $18.32 today.
